BRISBANE, Calif., July 26,
2024 /PRNewswire/ -- ReviR Therapeutics, an
AI-enabled biotechnology company focused on developing small
molecule RNA modulators for neurogenetic diseases, announced today
that it has successfully completed a $30
million Series A financing, bringing the total raised so far
to $54M, including the seed financing
in 2021. The financing was led by Lapam Capital with strong support
from existing investors CDH Investments, 5Y Capital, and Yael
Capital, as well as new participants XtalPi and the Charcot-Marie
Tooth Research Foundation (CMTRF).
These funds will be used to further augment ReviR's AI-driven
drug discovery VoyageR platform, which will be leveraged to advance
proprietary chemical matter for novel and undruggable targets and
to support clinical development of treatments for Huntington's
disease (HD), Charcot-Marie-Tooth disease (CMT), amyotrophic
lateral sclerosis (ALS), and other neurological disorders.
Since its founding in 2021, ReviR Therapeutics has assembled an
expert global drug discovery team and built a robust customized AI
platform. ReviR's platform strategy focuses on developing
non-invasive, orally administered genetic therapies that use small
molecules to regulate RNA splicing and influence protein
expression. This approach leverages the VoyageR platform to develop
potent, safe, and selective RNA splicing modulators for a broad
range of diseases.
While over 80% of disease-related proteins are considered
"undruggable", ReviR's novel genetic therapies target RNA, upstream
of protein synthesis to stop causal disease progression. Other
genetic therapy modalities often encounter delivery challenges,
particularly with crossing the blood-brain barrier, and can be
invasive, especially for CNS diseases. ReviR is currently focused
on treating neurodegenerative diseases and rare genetic disorders
while exploring partnerships in the fields of oncology, immunology
& inflammation, and metabolic diseases.
Dr. Peng Yue, Co-founder and CEO
of ReviR Therapeutics, stated, "Neurological diseases affect a
large number of individuals worldwide, many of which do not have
disease modifying therapies available. ReviR is dedicated to
developing accessible, safer genetic therapies that can be
administered orally. We value the support from new and existing
investors as we progress from initial platform development to
clinical trials, continually enhancing our AI platform and
advancing our pipeline. As we move forward, we will continue to
raise funds as an extension to our Series A to support additional
programs entering clinical trials."
Mr. Zhihua Yu, Founding Partner
of Lapam Capital, commented, "Small molecule targeting RNA
represents a highly challenging and innovative field. RNA targets
offer greater potential compared to protein targets, but also
present higher development difficulties. We have great confidence
in ReviR's platform, which can identify potential RNA targets and
efficiently develop safe and effective RNA-targeted therapies. This
enables the development of orally administrable small molecule
drugs for previously undruggable targets. ReviR has built a team
with extensive experience in computational biology, RNA biology,
and drug discovery, showcasing exceptional execution capabilities.
We are confident the company will advance its pipeline to clinical
trials soon, benefiting patients worldwide. We will continue to
support ReviR with our experience and resources as it
grows."
Dr. Shuhao Wen, Co-founder and
Chairman of XtalPi, added, "At XtalPi, we recognize the immense
potential of small molecule targeting RNA to significantly expand
the boundaries of drug discovery. Our collaboration with ReviR,
leveraging XtalPi's cutting-edge AI and robotics drug discovery
solutions with ReviR's specialized capabilities in RNA structural
analysis, small molecule screening, and target engagement
evaluation, has already yielded promising pipeline results. Our
collective expertise is aimed at propelling these innovations into
clinical research, tapping into the vast and underexplored
potential of RNA targets, and delivering effective novel
therapeutic options to patients worldwide."
About ReviR Therapeutics
ReviR Therapeutics is an emerging biopharmaceutical company
focused on the development of RNA-targeting small molecule
therapies that modulate the causal genes of diseases, including CNS
diseases, cancer, and other rare genetically-defined diseases. The
company is utilizing cutting-edge technologies to develop therapies
with the goal of developing disease modifying therapies that are
highly specific, efficacious, and safe. The company's initial focus
is to apply SpliceR modulation technologies towards RNA targets of
genetic diseases with limited or no treatment options. ReviR
Therapeutics was founded in 2021 by leaders in computational
biology, AI/ML, RNA biology, and drug discovery. The company is
headquartered in Brisbane, CA. For
more information, visit our website www.revirtx.com or
email info@revirtx.com.
About Lapam Capital
Lapam Capital is a leading healthcare venture capital firm
managing six funds with more than 1.5
billion dollars under management. Lapam Capital focuses on
investments in early to mid- stage fast-growing companies that have
innovative pharmaceuticals and medical devices. Its investment
portfolio currently consists of 120+ projects, of which innovative
drug therapeutics projects account for over 80%, including Betta
Pharma, RemeGen Co. Ltd., Gyre Therapeutics, Asieris
Pharmaceuticals, ImmuneOnco Biopharmaceuticals, Binhui Biotech,
Biostar Pharmaceuticals, Eyebright Medical Technology Ltd., and
many other companies with great potential. Lapam Capital has a
professional investment team with more than 20 years of
international and domestic biopharmaceutical industry R&D and
management experience and can provide comprehensive value-added
support for the invested companies.
About XtalPi Inc.
XtalPi Inc. ("QuantumPharm", stock code: 2228.HK) is a quantum
physics-based, AI-powered, and robotics-driven, innovative R&D
platform company. Established in 2015 by three postdoctoral
physicists at Massachusetts Institute of
Technology (MIT), the Company is
dedicated to driving intelligent and digital transformation in the
life sciences and materials sciences sectors. The Company combines
quantum physics, AI, cloud computing, and large-scale robotics to
provide R&D solutions and services for biomedicine, chemical,
renewable energy and advanced materials industries globally.
About Charcot-Marie Tooth Research Foundation
CMT Research Foundation (CMTRF) is a patient-led, non-profit
focused on delivering treatments and cures for CMT. The foundation
identifies significant obstacles or deficiencies impeding progress
toward a cure and seeks out collaborators to address these issues.
To date, CMTRF has funded 24 projects, of which 8 are completed. Of
those 8 completed projects, 5 have clinical candidates. CMTRF's
mission to invest in promising science with high potential of
leading to treatments and cures was proven effective and
ground-breaking when DTx Pharma with a CMTRF- backed program as its
lead candidate was acquired by Novartis for $1 billion. Founded by two patients who are
driven to expedite drug delivery to people who live with CMT, the
501(c)(3) federal tax-exempt organization is supported by personal
and corporate financial gifts.
View original
content:https://www.prnewswire.com/news-releases/revir-therapeutics-raises-30-million-series-a-financing-to-advance-its-proprietary-oral-genetic-medicines-for-multiple-cns-disorders-302206560.html
SOURCE ReviR Therapeutics